Compare Manchester United PLC (MANU) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Manchester United (MANU) trades at $20.60, up 1.73% with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $666.51M in 2025 but negative net income margins and ROE. Analyst sentiment is divided with 40% buy ratings, while cash flow trends show heavy investment spending offset by financing activities.

The stock presents a valuation disconnect opportunity with market cap below Forbes' franchise estimates, but faces execution risks from persistent losses and high debt load. Upside depends on Champions League revenue conversion and cost management, while downside risks include sustained profitability challenges in the competitive sports landscape.

Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.

The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.